Current Report Filing (8-k)
June 22 2020 - 8:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
June 19, 2020
NABRIVA THERAPEUTICS PLC
(Exact name of registrant as specified in
its charter)
Ireland
|
|
001-37558
|
|
Not Applicable
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification
No.)
|
25-28 North Wall Quay,
IFSC, Dublin 1, Ireland
|
|
Not Applicable
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (610) 816-6640
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Ordinary Shares, nominal value $0.01 per share
|
|
NBRV
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. x
On June 19, 2020, Nabriva Therapeutics plc issued a press release
announcing that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application
resubmission for CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections, including
acute pyelonephritis.
The press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NABRIVA THERAPEUTICS PLC
|
|
|
Date: June 22, 2020
|
By:
|
/s/ Gary Sender
|
|
|
Gary Sender
|
|
|
Chief Financial Officer
|
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2023 to Sep 2024